BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Salaga M, Mokrowiecka A, Zielinska M, Malecka-Panas E, Kordek R, Kamysz E, Fichna J. New Peptide Inhibitor of Dipeptidyl Peptidase IV, EMDB-1 Extends the Half-Life of GLP-2 and Attenuates Colitis in Mice after Topical Administration. J Pharmacol Exp Ther 2017;363:92-103. [PMID: 28724693 DOI: 10.1124/jpet.117.242586] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Shao S, Xu Q, Yu X, Pan R, Chen Y. Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions.Pharmacol Ther. 2020;209:107503. [PMID: 32061923 DOI: 10.1016/j.pharmthera.2020.107503] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 17.5] [Reference Citation Analysis]
2 Zatorski H, Salaga M, Zielińska M, Mokrowiecka A, Jacenik D, Krajewska WM, Małecka-Panas E, Fichna J. Colonic inflammation induces changes in glucose levels through modulation of incretin system. Pharmacol Rep 2021;73:1670-9. [PMID: 34535873 DOI: 10.1007/s43440-021-00327-y] [Reference Citation Analysis]
3 Melo FJ, Pinto-Lopes P, Estevinho MM, Magro F. The Role of Dipeptidyl Peptidase 4 as a Therapeutic Target and Serum Biomarker in Inflammatory Bowel Disease: A Systematic Review.Inflamm Bowel Dis. 2021;27:1153-1165. [PMID: 33295607 DOI: 10.1093/ibd/izaa324] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Bodnar RJ. Endogenous opiates and behavior: 2017. Peptides 2020;124:170223. [DOI: 10.1016/j.peptides.2019.170223] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
5 Olivares M, Schüppel V, Hassan AM, Beaumont M, Neyrinck AM, Bindels LB, Benítez-Páez A, Sanz Y, Haller D, Holzer P, Delzenne NM. The Potential Role of the Dipeptidyl Peptidase-4-Like Activity From the Gut Microbiota on the Host Health. Front Microbiol 2018;9:1900. [PMID: 30186247 DOI: 10.3389/fmicb.2018.01900] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 6.8] [Reference Citation Analysis]
6 Kato S, Utsumi D, Matsumoto K. G protein-coupled receptor 40 activation ameliorates dextran sulfate sodium-induced colitis in mice via the upregulation of glucagon-likepeptide-2. Journal of Pharmacological Sciences 2019;140:144-52. [DOI: 10.1016/j.jphs.2019.05.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
7 Azmy Nabeh O, Ishak Attallah M, El-Sayed El-Gawhary N. The pivotal relation between glucagon-like peptides, NFκB and inflammatory bowel disease. Clin Exp Pharmacol Physiol 2020;47:1641-8. [PMID: 32511781 DOI: 10.1111/1440-1681.13361] [Reference Citation Analysis]
8 Huang F, Ning M, Wang K, Liu J, Guan W, Leng Y, Shen J. Discovery of Highly Polar β-Homophenylalanine Derivatives as Nonsystemic Intestine-Targeted Dipeptidyl Peptidase IV Inhibitors. J Med Chem 2019;62:10919-25. [PMID: 31747282 DOI: 10.1021/acs.jmedchem.9b01649] [Reference Citation Analysis]
9 Salaga M, Binienda A, Draczkowski P, Kosson P, Kordek R, Jozwiak K, Fichna J. Novel peptide inhibitor of dipeptidyl peptidase IV (Tyr-Pro-D-Ala-NH2) with anti-inflammatory activity in the mouse models of colitis. Peptides 2018;108:34-45. [PMID: 30179653 DOI: 10.1016/j.peptides.2018.08.011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
10 Zatorski H, Sałaga M, Fichna J. Role of glucagon-like peptides in inflammatory bowel diseases-current knowledge and future perspectives.Naunyn Schmiedebergs Arch Pharmacol. 2019;392:1321-1330. [PMID: 31359088 DOI: 10.1007/s00210-019-01698-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
11 Chavira A, Belda-ferre P, Kosciolek T, Ali F, Dorrestein PC, Knight R. The Microbiome and Its Potential for Pharmacology. In: Barrett JE, Page CP, Michel MC, editors. Concepts and Principles of Pharmacology. Cham: Springer International Publishing; 2019. pp. 301-26. [DOI: 10.1007/164_2019_317] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
12 Li M, Weigmann B. A Novel Pathway of Flavonoids Protecting against Inflammatory Bowel Disease: Modulating Enteroendocrine System. Metabolites 2022;12:31. [PMID: 35050153 DOI: 10.3390/metabo12010031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
13 Radbakhsh S, Atkin SL, Simental-Mendia LE, Sahebkar A. The role of incretins and incretin-based drugs in autoimmune diseases. Int Immunopharmacol 2021;98:107845. [PMID: 34126341 DOI: 10.1016/j.intimp.2021.107845] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Villablanca EJ, Selin K, Hedin CRH. Mechanisms of mucosal healing: treating inflammatory bowel disease without immunosuppression? Nat Rev Gastroenterol Hepatol 2022. [PMID: 35440774 DOI: 10.1038/s41575-022-00604-y] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Arab HH, Eid AH, Mahmoud AM, Senousy MA. Linagliptin mitigates experimental inflammatory bowel disease in rats by targeting inflammatory and redox signaling. Life Sci 2021;273:119295. [PMID: 33667522 DOI: 10.1016/j.lfs.2021.119295] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Lashgari NA, Roudsari NM, Zandi N, Pazoki B, Rezaei A, Hashemi M, Momtaz S, Rahimi R, Shayan M, Dehpour AR, Abdolghaffari AH. Current overview of opioids in progression of inflammatory bowel disease; pharmacological and clinical considerations. Mol Biol Rep 2021;48:855-74. [PMID: 33394234 DOI: 10.1007/s11033-020-06095-x] [Reference Citation Analysis]
17 Verbeure W, van Goor H, Mori H, van Beek AP, Tack J, van Dijk PR. The Role of Gasotransmitters in Gut Peptide Actions. Front Pharmacol 2021;12:720703. [PMID: 34354597 DOI: 10.3389/fphar.2021.720703] [Reference Citation Analysis]
18 Ning MM, Yang WJ, Guan WB, Gu YP, Feng Y, Leng Y. Dipeptidyl peptidase 4 inhibitor sitagliptin protected against dextran sulfate sodium-induced experimental colitis by potentiating the action of GLP-2. Acta Pharmacol Sin 2020;41:1446-56. [PMID: 32398684 DOI: 10.1038/s41401-020-0413-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]